Although PD-1/PD-L1 inhibitors for cancer immunotherapy are currently in common use in oncology, their safety and efficacy are still unknown for patients with preexisting autoantibodies, which are recognized as biomarkers of autoimmune diseases. The gene discussed is PDCD1; the disease is autoimmune disease.